A holistic approach to Parkinson’s disease endpoint data collection: Efficacy, safety and quality of life
In this webinar, the expert speakers will comprehensively explore Parkinson’s disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life. The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.
Register to learn about the complexities of Parkinson’s disease endpoint data collection and obtain invaluable insights for improving patient outcomes and advancing therapeutic interventions.
Session information:
The speakers will present compelling evidence underscoring the heightened sensitivity of digital measures in monitoring Parkinson’s disease progression compared to conventional clinical scales. Furthermore, they will dissect the efficacy and quality of life evaluations by leveraging clinical rating scales, patient-reported outcomes and the distinctive utility of the on/off dyskinesia diary.
They will also review the significance of imaging features in accurately characterizing Parkinson’s disease biologically, paving the way for biomarker-guided drug development. Neuroimaging reveals striatal dopaminergic neuronal loss and the structure, function and integrity of motor circuitry throughout the brain. These circuits represent crucial targets for assessing patient eligibility, safety and therapeutic efficacy in the development of disease-modifying therapies.
Delving into safety considerations, the speakers will explore the impact of autonomic dysfunction associated with Parkinson’s disease, and the role for high-quality blood pressure data and heart rate variability analysis to characterize this. In addition, they will review QT interval monitoring strategies and some practical insights into implementing cardiac safety monitoring in this unique population.
Moderator
Todd Rudo, M.D.
Chief Medical Officer at Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety. Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high-quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Speakers
Vrutangkumar V. Shah, Ph.D.
Director, Data Science & Biostatistics, Precision Motion at Clario
Dr. Vrutangkumar V. Shah is a scientist with over 13 years of experience in clinical research. He is currently working as a Director, Data Science and Biostatistics at Clario, a global data and technology company that helps with decentralized clinical trials. He consults with sponsors and CROs in developing the Statistical Analysis Plan (SAP) package for Phase I-IV clinical studies. His expertise includes but is not limited to data analytics, biostatistics, machine learning and time-series analysis to develop digital biomarkers for clinical trials.
Laura Khurana, MPH
Principal Scientific Advisor at Clario
Laura Khurana is an experienced public health and clinical research professional with a special interest in electronic clinical outcome assessments (eCOAs) for clinical trials. Laura has 17 years of experience in the clinical research industry, initially working in web-based data collection for patient registries and post-approval safety studies. Laura has been at Clario for 10 years, and in her current role as Principal Scientific Advisor she is responsible for leading the scientific direction for eCOA services, including directing data collection design strategy based on best practices, knowledge of the literature, patient and site preferences and applicable regulations. She has experience supporting trials across a wide range of clinical indications, including multiple sclerosis, headache and migraine, dermatology and diabetes. Laura earned her MPH from Boston University School of Public Health, and her BA from the University of Georgia.
Dave Scott, Ph.D.
Vice President, Medical and Scientific Affairs, Neuroscience at Clario
Dr. David Scott, Ph.D., is Vice President, Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches, including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction. Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers and operational specialists on the design, execution, analysis and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefits to patients around the world.
Jeff Heilbraun, M.S.
Vice President, Medical Affairs, Cardiac Safety at Clario
Jeff Heilbraun is the Vice President of Medical and Scientific Affairs, Cardiac Safety at Clario. He completed his Bachelor of Science degree in Biology at Tufts University with a focus on physiology and his Master of Science in Health Promotion and Disease Management studies at the American University in Washington DC where he continued as an adjunct professor in the Health Promotion program. Throughout his career, Jeff has maintained his focus on the science, technology, trial design and regulatory considerations surrounding cardiac safety within pharmaceutical development. With his 30 years of experience with the Clario cardiac safety services team, Jeff has had the opportunity to support solutions for both safety and efficacy endpoints across a wide range of therapeutic indications. He has been fortunate to support both internal white papers and publications from a scientific and regulatory perspective in the area of blood pressure monitoring and endpoints